Option chain shows key data for Lisata Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lisata Therapeutics.

Lisata Therapeutics (NASDAQ:LSTA) Stock, Option Chain

Lisata Therapeutics

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

abbott shutter

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ABSI

AGYS

BLBX

HEPA

LSTA

Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales

Procter & Gamble p&g shutter

Nasdaq Surges 1.5%; Procter &amp; Gamble Posts Upbeat Earnings

Programmer,Working,In,A,Software,Developing,Company,Office

ASST

NFLX

STFS

US Stocks Higher; Netflix Profit Beats Estimates

Lisata Therapeutics Inc

Press Releases

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

Health Care

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

General

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Lisata Therapeutics to Present at the Investival Showcase USA

Lisata Therapeutics Announces Research License with Catalent

Abpro Hldgs

ABVC BioPharma

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioAtla

BioVie

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Curis

CEL-SCI

Elevation Oncology

Equillium

GlycoMimetics

Kala Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Leap Therapeutics

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Nanoviricides

Ovid Therapeutics

Passage Bio

Q32 Bio

SAB Biotherapeutics

Tenax Therapeutics

Unity Biotechnology

HC Wainwright & Co.

Comments

Lisata Therapeutics

Lisata Therapeutics (LSTA) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell